首页|磁共振T2加权像、动态增强扫描序列参数在前列腺癌中的表现及与前列腺特异性抗原水平、国际泌尿病理学会分级的相关性

磁共振T2加权像、动态增强扫描序列参数在前列腺癌中的表现及与前列腺特异性抗原水平、国际泌尿病理学会分级的相关性

扫码查看
目的 探讨磁共振T2 加权像(T2WI)、磁共振动态增强扫描(DCE-MRI)参数在前列腺癌中的表现及与前列腺特异性抗原(PSA)、国际泌尿病理学会(ISUP)分级的相关性.方法 选取 2019 年 3 月至 2023 年 6 月在宜兴市中医医院就诊的82 例前列腺病变患者作为研究对象,其中前列腺癌患者 52 例,前列腺增生患者 30 例,比较不同患者T2WI、DCE-MRI序列参数.结果 前列腺癌患者T2WI表现≥4 分的比例为 50.00%,高于前列腺增生患者(P<0.05);前列腺癌患者峰值时间(Tmax)为70 541.44(45 035.20,90 655.41)ms,短于前列腺增生患者(P<0.05),而最快强化率(Rmax)为(36.60±14.41),高于前列腺增生患者(P<0.05).Ⅲ~Ⅳ期、ISUP分级≥4 级、PSA水平≥50 ng/ml的前列腺癌患者T2WI表现≥4 分的比例分别为 62.50%、75.00%和 63.16%,高于Ⅰ~Ⅱ期、ISUP分级≤3 级和PSA水平<50 ng/ml患者(P<0.05);Ⅲ~Ⅳ期的前列腺癌患者Tmax为68 405.44(43 506.43,82 204.32)ms,短于Ⅰ~Ⅱ期患者(P<0.05),而Rmax为(39.16±9.50),高于Ⅰ~Ⅱ期患者(P<0.05);ISUP分级≥4 级的前列腺癌患者Tmax为 66 504.32(43 506.43,84 053.12)ms,短于ISUP分级≤3 级患者(P<0.05),而Rmax为(40.38±9.75),高于ISUP分级≤3 级患者(P<0.05);PSA水平≥50 ng/ml的患者Tmax为 63 044.22(45 035.20,82 204.32)ms,短于PSA水平<50 ng/ml的患者(P<0.05),而Rmax为(39.15±9.05),高于PSA水平<50 ng/ml的患者(P<0.05);Tmax与PSA呈负相关(P<0.05),Rmax与PSA呈正相关(P<0.05);T2WI表现和Rmax与ISUP分级呈正相关(P<0.05),Tmax与ISUP分级呈负相关(P<0.05).结论 T2WI、DCE-MRI序列参数与前列腺癌临床分期、ISUP分级、PSA水平存在相关性,值得临床进一步研究.
T2WI and DCE-MRI parameters in patients with prostate cancer and their correlations with PSA level and ISUP grading
Objective To explore the presentation of T2 weighted magnetic resonance imaging(T2WI)and dynamic contrast-enhanced magnetic resonance imaging(DCE-MRI)parameters in patients with prostate cancer and their correlations with prostate specific antigen(PSA)level and International Society of Urological pathology(ISUP)grading.Methods A total of 82 patients with prostate diseases who were admitted to Yixing Traditional Chinese Medicine Hospital between March 2019 and June 2023 were selected as research objects,including 52 patients with prostate cancer and 30 patients with benign prostatic hyperplasia.T2WI and DCE-MRI parameters of these patients were compared.Results The proportion of prostate cancer patients with T2WI score≥4 was 50.00%,which was higher than that of the benign prostatic hyperplasia patients(P<0.05).The peak time(Tmax)of prostate cancer patients was 70 541.44(45 035.20,90 655.41)ms,which was shorter than that of the patients with benign prostatic hyperplasia(P<0.05).The fastest enhancement rate(Rmax)of prostate cancer patients was 36.60±14.41,which was higher than that in patients with benign prostatic hyperplasia(P<0.05).The proportions of patients with T2WI score≥4 in stages Ⅲ-Ⅳ,ISUP grading≥4,and PSA≥50 ng/ml were 62.50%,75.00%and 63.16%,respectively,which were significantly higher than those in stages Ⅰ-Ⅱ,ISUP grading≤3,and PSA level<50 ng/ml(all P<0.05).The Tmax of patients in stages Ⅲ-Ⅳ was 68 405.44(43 506.43,82 204.32)ms,which was lower than that of stagesⅠ-Ⅱpatients(all P<0.05).The Rmax of patients in stages Ⅲ-Ⅳ was 39.16±9.50,which was higher than that of stages Ⅰ-Ⅱ patients(all P<0.05).The Tmax of patients with ISUP grading≥4 was 66 504.32(43 506.43,84 053.12)ms,which was lower than that of patients with ISUP grading≤3(P<0.05).The Rmax of patients with ISUP grading≥4 was 40.38±9.75,which was higher than that of patients with ISUP grading≤3(P<0.05).The Tmax of patients with PSA≥50 ng/ml was 63 044.22(45 035.20,82 204.32)ms,which was shorter than that of patients with PSA<50 ng/ml(P<0.05).The Rmax of patients with PSA≥50 ng/ml was 39.15±9.05,which was higher than that of patients with PSA<50 ng/ml(P<0.05).Tmax was negatively correlated with PSA(P<0.05),while Rmax was positively correlated with PSA(P<0.05).T2WI manifestations and Rmax were positively correlated with ISUP grading(all P<0.05),while Tmax was negatively correlated with ISUP grading(P<0.05).Conclusion T2WI and DCE-MRI parameters are correlated with clinical staging,ISUP grading,and PSA level of prostate cancer,which is worthy of further clinical research.

T2 weighted magnetic resonance imagingDynamic contrast-enhanced magnetic resonance imagingProstate cancerProstate-specific antigenInternational Society of Urology Pathology grading

张蔓、吕军浩、马辉、赵勤余、方旭俭、林沐

展开 >

214200 江苏 宜兴,宜兴市中医医院影像科

磁共振T2加权像 磁共振动态增强扫描 前列腺癌 前列腺特异性抗原 国际泌尿病理学会分级

2024

海军医学杂志
海军医学研究所

海军医学杂志

CSTPCD
影响因子:0.518
ISSN:1009-0754
年,卷(期):2024.45(7)